TLPH

+ Watchlist + Portfolio

Talphera, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.19
52-Week Range: $0.47 – $1.57
Market Cap: $61.77M
P/E (TTM): —
EPS (TTM): -0.23
Dividend Yield: —

Advanced Metrics

Price/Book: 3.22
PEG Ratio: —
Return on Equity: -143.36%
Return on Assets: -42.55%
Gross Margin: 0.00%
Operating Margin: -1474700.00%
Profit Margin: 0.00%
Current Ratio: 4.29
Debt/Equity: 0.45
Total Debt: $6.50M
Free Cash Flow: $-6.87M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $51.19M

TLPH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$651.00K	$0.00	$28.00K
Cost of Revenue	$2.59M	—	—	—
Gross Profit	-$820.00K	—	—	—
Research & Development	$3.34M	$5.55M	$6.72M	$6.03M
Selling, General & Admin	$17.01M	$11.99M	$8.53M	$7.48M
Operating Expenses	$20.35M	$17.54M	$15.25M	$13.51M
Operating Income	-$20.35M	-$16.89M	-$15.25M	-$13.48M
EBITDA	$61.90M	-$9.84M	-$12.61M	-$14.36M
Pretax Income	$59.14M	-$10.29M	-$13.00M	-$14.36M
Income Tax	$13.00K	$0.00	—	—
Net Income	$47.76M	-$18.40M	-$13.00M	-$14.29M
Diluted EPS	5.72	-1.29	-0.50	-0.34
Diluted Shares	7.41M	14.26M	25.85M	42.41M

TLPH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$15.28M	$5.72M	$8.86M	$5.89M
Receivables	$309.00K	—	—	—
Inventory	$1.18M	—	—	—
Current Assets	$24.57M	$11.58M	$9.42M	$20.90M
Total Assets	$47.49M	$20.39M	$18.24M	$29.72M
Current Liabilities	$13.77M	$4.51M	$2.65M	$3.81M
Total Debt	$5.36M	—	—	—
Total Liabilities	$25.67M	$6.29M	$10.23M	$12.68M
Retained Earnings	-$425.83M	-$444.23M	-$457.23M	-$471.52M
Shareholders' Equity	$21.81M	$14.11M	$8.00M	$17.04M
Working Capital	$10.80M	$7.06M	$6.77M	$17.09M

TLPH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$28.33M	-$17.49M	-$12.68M	-$11.36M
Capital Expenditure	-$364.00K	-$100.00K	—	—
Free Cash Flow	-$28.70M	-$17.59M	-$12.68M	-$11.36M
Depreciation & Amortisation	$1.65M	$311.00K	$0.00	—
Stock-Based Compensation	$2.89M	$1.73M	$989.00K	$699.00K
Investing Cash Flow	$36.45M	-$528.00K	$3.78M	-$14.35M
Financing Cash Flow	-$507.00K	$3.47M	$12.04M	$22.74M
Share Repurchases	-$315.00K	$0.00	—	—
Net Change in Cash	$7.61M	-$14.55M	$3.14M	-$2.97M

TLPH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$27.00K	$0.00	$1.00K	$0.00	$0.00
Research & Development	$1.17M	$1.50M	$1.80M	$1.56M	$1.65M
Selling, General & Admin	$1.77M	$2.19M	$1.62M	$1.89M	$2.30M
Operating Expenses	$2.94M	$3.69M	$3.42M	$3.45M	$3.95M
Operating Income	-$2.92M	-$3.69M	-$3.42M	-$3.45M	-$3.95M
EBITDA	-$2.92M	-$3.49M	-$4.44M	-$3.77M	-$3.95M
Pretax Income	-$2.67M	-$3.49M	-$4.44M	-$3.77M	-$2.56M
Net Income	-$2.59M	-$3.49M	-$4.44M	-$3.77M	-$2.56M
Diluted EPS	-0.10	-0.10	-0.11	-0.06	-0.04
Diluted Shares	26.27M	34.53M	41.45M	66.95M	69.82M

TLPH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$5.39M	$6.79M	$3.46M	$5.89M	$3.82M
Current Assets	$6.18M	$7.70M	$21.92M	$20.90M	$21.34M
Total Assets	$14.99M	$16.52M	$30.74M	$29.72M	$30.16M
Current Liabilities	$1.99M	$2.63M	$3.21M	$3.81M	$4.03M
Total Liabilities	$9.40M	$9.89M	$11.56M	$12.68M	$11.68M
Retained Earnings	-$459.82M	-$463.31M	-$467.75M	-$471.52M	-$474.08M
Shareholders' Equity	$5.60M	$6.63M	$19.18M	$17.04M	$18.48M
Working Capital	$4.19M	$5.07M	$18.71M	$17.09M	$17.31M

TLPH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.47M	-$2.95M	-$2.51M	-$2.44M	-$3.40M
Free Cash Flow	-$3.47M	-$2.95M	-$2.51M	-$2.44M	-$3.40M
Stock-Based Compensation	$196.00K	$166.00K	$152.00K	$185.00K	$214.00K
Investing Cash Flow	$0.00	$0.00	-$17.82M	$3.47M	-$2.71M
Financing Cash Flow	-$5.00K	$4.35M	$16.99M	$1.40M	$4.04M
Net Change in Cash	-$3.48M	$1.40M	-$3.33M	$2.44M	-$2.07M

Market Snapshot

About

Talphera, Inc. is a pharmaceutical company focused on developing and commercializing therapies for rare bleeding and thrombotic diseases. The company is advancing treatments for patients with critical unmet medical needs in hematology.